Julia Jauch-Lembach

Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches

Andrew Blauvelt, J.‐P. Lacour, Joseph F. Fowler et al. · British Journal of Dermatology · 2018 · 147 citations

Medicine, Clinical Sciences, Pharmacotherapy +14

Switching to Biosimilar SDZ-ADL in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: 48-Week Efficacy, Safety and Immunogenicity Results From the Phase III, Randomized, Double-Blind ADMYRA Study

Piotr Wiland, Sławomir Jeka, Eva Dokoupilová et al. · BioDrugs · 2020 · 38 citations · Full text

Medicine, Immunology, Pharmacology +17

GP2017, an adalimumab biosimilar: pharmacokinetic similarity to its reference medicine and pharmacokinetics comparison of different administration methods

Oliver von Richter, Lena Lemke, Halimu N. Haliduola et al. · Expert Opinion on Biological Therapy · 2019 · 36 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Phase 1b/2a Study Assessing the Safety and Efficacy of Felzartamab in Anti-Phospholipase A2 Receptor Autoantibody–Positive Primary Membranous Nephropathy

Brad H. Rovin, Pierre Ronco, Jack F.M. Wetzels et al. · Kidney International Reports · 2024 · 28 citations · Full text

Medicine, Nephrology, Pharmacology +10

Treatment with SDZ-ADL, an Adalimumab Biosimilar, in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis: Results of Patient-Reported Outcome Measures from Two Phase III Studies (ADMYRA and ADACCESS)

Andrew Blauvelt, Craig L. Leonardi, Norman Gaylis et al. · BioDrugs · 2021 · 21 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +15